Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014)
Insmed's (INSM) quarterly Non-Current Deffered Revenue came in at $118000.0 in Q4 2014, down 68.95% year-on-year from $380000.0 in Q4 2013, and down 36.22% quarter-over-quarter from $185000.0 in Q3 2014.
Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014) Analysis & Trends
Insmed's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $118000.0 for Q4 2014.
- On a quarterly basis, Non-Current Deffered Revenue fell 68.95% year-over-year to $118000.0 in Q4 2014; TTM through Dec 2014 was $118000.0, a 68.95% decrease from a year earlier, with the FY2014 full-year figure at $118000.0, down 68.95% from the prior year.
- Non-Current Deffered Revenue retreated to $118000.0 in Q4 2014 per INSM's latest filing, from $185000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $647000.0 in Q4 2012 and bottomed at $118000.0 in Q4 2014.
- The 3-year median for Non-Current Deffered Revenue is $380000.0 (2013), against an average of $382000.0.
- Across the five-year window, Non-Current Deffered Revenue slumped 41.27% in 2013 and tumbled 68.95% in 2014, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $647000.0 in 2012, then slumped by 41.27% to $380000.0 in 2013, then tumbled by 68.95% to $118000.0 in 2014.
- Per Business Quant, the three latest INSM Non-Current Deffered Revenue figures stand at $118000.0 (Q4 2014), $185000.0 (Q3 2014), and $250000.0 (Q2 2014).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 118,000.00 |
| Sep 30, 2014 | 185,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Mar 31, 2014 | 315,000.00 |
| Dec 31, 2013 | 380,000.00 |
| Sep 30, 2013 | 449,000.00 |
| Jun 30, 2013 | 514,000.00 |
| Mar 31, 2013 | 580,000.00 |
| Dec 31, 2012 | 647,000.00 |